[go: up one dir, main page]

PE20130149A1 - Derivados de la cromenona con actividad anti-tumoral - Google Patents

Derivados de la cromenona con actividad anti-tumoral

Info

Publication number
PE20130149A1
PE20130149A1 PE2012000578A PE2012000578A PE20130149A1 PE 20130149 A1 PE20130149 A1 PE 20130149A1 PE 2012000578 A PE2012000578 A PE 2012000578A PE 2012000578 A PE2012000578 A PE 2012000578A PE 20130149 A1 PE20130149 A1 PE 20130149A1
Authority
PE
Peru
Prior art keywords
ethyl
alkyl
halogen
chromenone
alcoxy
Prior art date
Application number
PE2012000578A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
Sebastien Louis Degorce
Der Brempt Christine Marie Paul Lambert-Van
Remy Robert Morgentin
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20130149A1 publication Critical patent/PE20130149A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE CROMENONA DE FORMULA (I) DONDE R1 ES H O ALQUILO(C1-C4) OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI O ALCOXI(C1-C3); R2 ES ALQUILO(C1-C4) O ALCOXI(C1-C4) OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI, ALQUENILO(C2-C3), ENTRE OTROS; R3 ES H O ALQUILO(C1-C3); R4 Y R5 SON CADA UNO H, HALOGENO, ALQUILO(C1-C3), ALQUENILO(C2-C3), CN, ENTRE OTROS; R6, R7 Y R8 SON CADA UNO H, HALOGENO, ALQUILO(C1-C3), ALCOXI(C1-C3), ENTRE OTROS; R9 ES ALQUILO(C1-C3); n ES DE 0 A 4. SON COMPUESTOS PREFERIDOS: N-(2-(DIMETILAMINO)ETIL)-8-(1-(4-FLUOROFENILAMINO)ETIL)-2-MORFOLINO-4-OXO-4H-CROMENO-6-CARBOXAMIDA; N-(2-(DIMETILAMINO)ETIL)-2-MORFOLINO-4-OXO-8-(1-(FENILAMINO)ETIL)-4H-CROMENO-6-CARBOXAMIDA; 8-(1-(3-CLORO-2-FLUOROFENILAMINO)ETIL)-N-(2-(DIMETILAMINO)ETIL)-2-MORFOLINO-4-OXO-4H-CROMENO-6-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE FOSFOINOSITIDA (PI) 3-QUINASA ? SIENDO UTILES EN EL TRATAMIENTO DE CANCER
PE2012000578A 2009-10-27 2010-10-25 Derivados de la cromenona con actividad anti-tumoral PE20130149A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09306017 2009-10-27

Publications (1)

Publication Number Publication Date
PE20130149A1 true PE20130149A1 (es) 2013-03-10

Family

ID=43085922

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000578A PE20130149A1 (es) 2009-10-27 2010-10-25 Derivados de la cromenona con actividad anti-tumoral

Country Status (41)

Country Link
US (5) US8399460B2 (es)
EP (1) EP2493870B1 (es)
JP (2) JP5657010B2 (es)
KR (1) KR101738195B1 (es)
CN (2) CN102712615B (es)
AR (1) AR078786A1 (es)
AU (1) AU2010311107B9 (es)
BR (1) BR112012010124B8 (es)
CA (1) CA2776994C (es)
CL (1) CL2012001056A1 (es)
CO (1) CO6541528A2 (es)
CR (1) CR20120217A (es)
CU (1) CU20120069A7 (es)
CY (1) CY1116143T1 (es)
DK (1) DK2493870T3 (es)
DO (1) DOP2012000124A (es)
EA (1) EA020523B9 (es)
EC (1) ECSP12011838A (es)
ES (1) ES2530943T3 (es)
GT (1) GT201200126A (es)
HN (1) HN2012000889A (es)
HR (1) HRP20150146T1 (es)
IL (1) IL219191A0 (es)
IN (1) IN2012DN03328A (es)
ME (1) ME02050B (es)
MX (1) MX2012005027A (es)
MY (1) MY179833A (es)
NI (1) NI201200081A (es)
NZ (1) NZ599457A (es)
PE (1) PE20130149A1 (es)
PH (1) PH12012500804A1 (es)
PL (1) PL2493870T3 (es)
PT (1) PT2493870E (es)
RS (1) RS53813B1 (es)
SA (1) SA110310808B1 (es)
SI (1) SI2493870T1 (es)
SM (1) SMT201500036B (es)
TW (1) TWI483939B (es)
UA (1) UA107474C2 (es)
UY (1) UY32978A (es)
WO (1) WO2011051704A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX315904B (es) 2008-05-30 2013-11-29 Amgen Inc Inhibidores de fosfoinosituro-3 cinasa.
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
US8530470B2 (en) 2011-04-13 2013-09-10 Astrazeneca Ab Chromenone derivatives
CA2897279C (en) 2013-01-23 2020-12-29 Astrazeneca Ab Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer
CN105142629B (zh) * 2013-03-04 2018-11-23 阿斯利康(瑞典)有限公司 组合治疗
NZ726055A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
HK1231476A1 (zh) 2014-06-13 2017-12-22 吉利德科学公司 磷脂酰肌醇3-激酶抑制剂
WO2015191745A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP3154962B1 (en) 2014-06-13 2019-08-07 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MX2016016516A (es) 2014-06-13 2017-05-01 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-cinasa.
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
JP6912460B2 (ja) * 2015-10-09 2021-08-04 ヤンセン ファーマシューティカ エヌ．ベー． ＰＩ３Ｋβ阻害剤としてのキノキサリンおよびピリドピラジン誘導体
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR121719A1 (es) 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
KR20210141214A (ko) * 2020-05-15 2021-11-23 제이투에이치바이오텍 (주) 3원환 화합물 및 이의 의약 용도
EP4284375A4 (en) * 2021-02-01 2025-04-23 Geode Therapeutics Inc. PHOSPHOINOSITIDE 3-KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREFOR
MX2023013082A (es) * 2021-05-03 2024-01-08 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades.
EP4333984A1 (en) * 2021-05-03 2024-03-13 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh) * 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20250084048A1 (en) * 2021-10-07 2025-03-13 Relay Therapeutics, Inc. Pi3k-alpha inhibitors and methods of use thereof
CN118742545A (zh) * 2021-12-08 2024-10-01 南京征祥医药有限公司 作为PI3Kα抑制剂的稠合杂环化合物
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
WO2024081904A1 (en) * 2022-10-14 2024-04-18 Genesis Therapeutics, Inc. Methods for treating cancer
CN119431297A (zh) * 2023-08-02 2025-02-14 郑州同源康医药有限公司 稠环类化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6027A (en) * 1849-01-09 Rotary blacksmith s twyer
FI912995A7 (fi) 1988-12-21 1991-06-19 Upjohn Co Antiateroskleroottisia ja antitromboottisia 1-bentsopyran-4-oneja ja 2 -amino-1,3-bentsoksatsin-4-oneja
WO1991019707A2 (en) 1990-06-20 1991-12-26 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DE4318756A1 (de) 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT880508E (pt) 1996-02-13 2003-07-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
CZ305827B6 (cs) 1999-02-10 2016-03-30 Astrazeneca Ab Indolové deriváty
AU3042601A (en) 2000-01-24 2001-07-31 Thrombogenix Pty Ltd Therapeutic morpholino-substituted compounds
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
EP1537102A4 (en) 2002-08-16 2010-12-08 Astrazeneca Ab INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
CA2620248A1 (en) 2005-10-21 2007-04-26 Merz Pharma Gmbh & Co. Kgaa Chromenones and their use as modulators of metabotropic glutamate receptors
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2112145A1 (en) 2008-04-24 2009-10-28 AxoGlia Therapeutics S.A. Chromenone derivatives useful for the treatment of neurodegenerative diseases
WO2010134082A1 (en) 2009-05-21 2010-11-25 Proteologics Ltd Chromenone derivatives for treatment of cancer
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
US20110098271A1 (en) 2011-04-28
US8399460B2 (en) 2013-03-19
PH12012500804A1 (en) 2022-10-03
CO6541528A2 (es) 2012-10-16
HK1206335A1 (zh) 2016-01-08
IL219191A0 (en) 2012-06-28
IN2012DN03328A (es) 2015-10-23
HK1174027A1 (en) 2013-05-31
BR112012010124B8 (pt) 2021-05-25
MY179833A (en) 2020-11-17
WO2011051704A1 (en) 2011-05-05
CN102712615B (zh) 2014-12-17
BR112012010124A2 (pt) 2016-06-07
US20130158026A1 (en) 2013-06-20
SA110310808B1 (ar) 2013-11-24
ES2530943T3 (es) 2015-03-09
KR20120098724A (ko) 2012-09-05
AR078786A1 (es) 2011-11-30
UY32978A (es) 2011-05-31
AU2010311107B9 (en) 2014-06-19
TW201121960A (en) 2011-07-01
NI201200081A (es) 2012-11-07
DOP2012000124A (es) 2012-07-15
CN102712615A (zh) 2012-10-03
AU2010311107B2 (en) 2014-03-27
BR112012010124B1 (pt) 2021-02-17
US20140194419A1 (en) 2014-07-10
CN104447657A (zh) 2015-03-25
CL2012001056A1 (es) 2012-10-05
CN104447657B (zh) 2016-08-17
RS53813B1 (sr) 2015-06-30
CA2776994C (en) 2017-10-31
SI2493870T1 (sl) 2015-03-31
EP2493870A1 (en) 2012-09-05
US8673906B2 (en) 2014-03-18
GT201200126A (es) 2014-03-03
US20160060240A1 (en) 2016-03-03
JP2013508449A (ja) 2013-03-07
EA020523B9 (ru) 2015-01-30
CR20120217A (es) 2012-06-28
UA107474C2 (uk) 2015-01-12
EP2493870B1 (en) 2014-12-17
ME02050B (me) 2015-05-20
PL2493870T3 (pl) 2015-04-30
SMT201500036B (it) 2015-05-05
US20160272607A1 (en) 2016-09-22
TWI483939B (zh) 2015-05-11
EA020523B1 (ru) 2014-11-28
CU20120069A7 (es) 2012-10-15
NZ599457A (en) 2014-04-30
HRP20150146T1 (hr) 2015-05-22
HN2012000889A (es) 2015-08-03
CY1116143T1 (el) 2017-02-08
MX2012005027A (es) 2012-09-07
JP2015078202A (ja) 2015-04-23
KR101738195B1 (ko) 2017-05-19
DK2493870T3 (en) 2015-02-23
AU2010311107A1 (en) 2012-05-03
CA2776994A1 (en) 2011-05-05
US9029374B2 (en) 2015-05-12
JP5657010B2 (ja) 2015-01-21
US9718800B2 (en) 2017-08-01
EA201200618A1 (ru) 2012-12-28
JP5872016B2 (ja) 2016-03-01
PT2493870E (pt) 2015-02-18
ECSP12011838A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
PE20221264A1 (es) Inhibidores de egfr
AR076460A1 (es) Antagonistas del receptor cxcr3
CY1118969T1 (el) Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
PE20091561A1 (es) Compuestos inhibidores de raf y metodos para su uso
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
EA201071370A1 (ru) Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
UY31254A1 (es) Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
CO2017000438A2 (es) Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble
NI201300111A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida

Legal Events

Date Code Title Description
FG Grant, registration